Primary Recipient

PHARMAREVIEW CORPORATION

Amount

$2,977,916.00

Award Date

9/07/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

The Specific Aims of the proposal is modified to reflect a change in scope, according to recommendations from the review panel. The aims of this Phase II continuation proposal are to utilize fully humanized recombinant lactoferrin (rhLF) as an adjuvant

Recipients Connected to Award

Recipient	Role	Amount
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	Sub-recipient	$822,583.00
UNIVERSITY OF NEBRASKA	Sub-recipient	$796,910.00
PHARMAREVIEW CORPORATION	Primary recipient	$778,908.00
GENSCRIPT USA INCORPORATED	Sub-recipient	$579,515.00